Thyroxine Dose Titration in Patients Already on Treatment

Initial Assessment Before Dose Adjustment

Before adjusting levothyroxine, measure both TSH and free T4 to distinguish between adequate replacement, undertreatment, and overtreatment. 1

Wait 6-8 weeks after any dose change before rechecking thyroid function tests, as this represents the time needed to reach steady state given levothyroxine's long half-life 2, 1
For patients with atrial fibrillation, cardiac disease, or other serious medical conditions, consider more frequent monitoring within 2 weeks rather than waiting the full 6-8 weeks 2
Measure TSH using a sensitive assay (second generation sensitivity ≤0.1 mIU/L or third generation ≤0.01 mIU/L) 1

Increase levothyroxine by 12.5-25 mcg increments based on the patient's current dose and clinical characteristics. 2

For patients <70 years without cardiac disease, use 25 mcg increments for more aggressive titration 2
For patients >70 years or with cardiac disease, use smaller 12.5 mcg increments to avoid cardiac complications 2, 1
If TSH >10 mIU/L, increase the dose regardless of symptoms, as this level carries approximately 5% annual risk of progression to overt hypothyroidism 2
Larger dose adjustments should be avoided as they may lead to overtreatment and iatrogenic hyperthyroidism 2

Decrease levothyroxine dose by 25-50 mcg immediately to prevent serious cardiovascular and bone complications. 2

First, review the indication for thyroid hormone therapy—management differs for thyroid cancer patients requiring TSH suppression versus primary hypothyroidism 2
For patients taking levothyroxine for hypothyroidism without thyroid cancer or nodules, dose reduction is mandatory 2
If prescribed for thyroid cancer, consult with the treating endocrinologist, as even most thyroid cancer patients should not have TSH severely suppressed 2
Prolonged TSH suppression significantly increases risk for atrial fibrillation (especially in elderly), osteoporosis, fractures, and cardiovascular mortality 2, 3, 4

Reduce levothyroxine dose by 12.5-25 mcg, particularly if TSH is in the lower part of this range or in patients with cardiac risk factors. 2

This level carries intermediate risk of atrial fibrillation and bone loss, particularly in postmenopausal women 2
Consider more aggressive dose reduction in patients >60 years or with cardiac disease 2

No dose adjustment is needed—continue current dose and monitor annually. 2, 1

Once adequately treated, repeat TSH testing every 6-12 months or sooner if symptoms change 2, 1
Target TSH should be maintained in the reference range with normal free T4 levels 2

Start with lower doses (25-50 mcg/day) and titrate gradually with smaller increments (12.5 mcg) 2, 1
Elderly patients may require less than 1 mcg/kg/day for full replacement 1, 5
Target TSH of 0.5-4.5 mIU/L is appropriate, though slightly higher targets may be acceptable in very elderly patients to avoid overtreatment risks 2

Use conservative titration with 12.5 mcg increments at 6-8 week intervals 2, 1
For elderly patients with cardiac disease, start at 12.5-25 mcg/day with gradual dose increments at 4-6 week intervals 1
Rapid normalization of thyroid hormone can unmask or worsen cardiac ischemia 2, 4
Assess for new or worsening angina, palpitations, dyspnea, or arrhythmias at each follow-up 2

Levothyroxine requirements typically increase 25-50% during pregnancy 2
More aggressive normalization of TSH is warranted, as subclinical hypothyroidism during pregnancy is associated with preeclampsia, low birth weight, and neurodevelopmental effects 2
Monitor thyroid function more frequently during pregnancy 2

Avoid overtreatment, as even slight overdose carries significant risk of osteoporotic fractures, especially in postmenopausal women 2, 3, 4
Ensure adequate calcium (1200 mg/day) and vitamin D (1000 units/day) intake if TSH is chronically suppressed 2
Target TSH in the mid-normal range rather than low-normal to minimize bone loss 2

Never adjust doses more frequently than every 6-8 weeks before reaching steady state 2, 1
Avoid excessive dose increases that could lead to iatrogenic hyperthyroidism, which increases risk for osteoporosis, fractures, atrial fibrillation, and ventricular hypertrophy 2, 3
Approximately 25% of patients on levothyroxine are unintentionally maintained on doses sufficient to fully suppress TSH, increasing serious complication risks 2
In patients with suspected concurrent adrenal insufficiency, start corticosteroids before increasing thyroid hormone to prevent adrenal crisis 2
Free T4 can help interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize 2

Recheck TSH and free T4 in 6-8 weeks after dose adjustment 2, 1
For patients with cardiac disease or atrial fibrillation, consider repeating testing within 2 weeks 2
Once the appropriate maintenance dose is established, monitor TSH annually or sooner if symptoms change 2, 1
A physical examination and serum TSH measurement should be performed at least annually 1